Risperidone and Metabolite, Serum or Plasma

Casandra

Casandra Test Code AR13320Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 2007951CPT Codes 0480, 80342

Risperidone and Metabolite, Serum or Plasma

Also known as: RISPERIDON

Clinical Use

Order Test

Use

The test is designed to optimize drug therapy and monitor patient adherence by detecting risperidone (parent) and paliperidone (9-hydroxyrisperidone, metabolite) in serum or plasma. It helps in ensuring the therapeutic range is achieved for effective treatment while minimizing toxic effects. Adverse effects to risperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension, and dyskinesia.

Special Instructions

Collect pre-dose (trough) sample after reaching steady-state concentration. Preferred collection in a plain red, lavender (EDTA), or pink (K2EDTA) tube. Separate serum or plasma from cells as soon as possible or within 2 hours of collection. Transfer at least 1 mL to ARUP Standard Transport Tube. Do not use gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).

Limitations

This test has been developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration, but is intended for clinical use. Whole blood and specific tube types (gel separator tubes, light blue, or yellow tubes) are not acceptable for this test. Results are based on pre-dose (trough) draw at steady-state concentration. The therapeutic range is 20-60 ng/mL for each compound, with toxicity above 120 ng/mL for combined measurements of risperidone and metabolite.

Test Details

New York Approved